Wedbush Predicts Increased Earnings for Stoke Therapeutics

Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Investment analysts at Wedbush increased their FY2024 earnings estimates for shares of Stoke Therapeutics in a note issued to investors on Tuesday, November 5th. Wedbush analyst L. Chico now expects that the company will post earnings per share of ($2.00) for the year, up from their previous forecast of ($2.03). Wedbush currently has a "Outperform" rating and a $17.00 target price on the stock. The consensus estimate for Stoke Therapeutics' current full-year earnings is ($2.10) per share. Wedbush also issued estimates for Stoke Therapeutics' Q3 2025 earnings at ($0.62) EPS, FY2025 earnings at ($2.40) EPS, FY2026 earnings at ($2.51) EPS, FY2027 earnings at ($2.05) EPS and FY2028 earnings at ($0.76) EPS.

A number of other analysts also recently issued reports on STOK. Needham & Company LLC reiterated a "buy" rating and issued a $22.00 price target on shares of Stoke Therapeutics in a report on Wednesday. Leerink Partnrs upgraded shares of Stoke Therapeutics to a "strong-buy" rating in a report on Friday, October 11th. HC Wainwright reissued a "buy" rating and issued a $35.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday. Finally, Leerink Partners initiated coverage on shares of Stoke Therapeutics in a research note on Monday, October 14th. They issued an "outperform" rating and a $18.00 price objective for the company. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Stoke Therapeutics currently has a consensus rating of "Buy" and an average price target of $20.83.

Stoke Therapeutics Stock Performance

NASDAQ STOK traded up $0.61 on Friday, reaching $13.88. The company had a trading volume of 419,252 shares, compared to its average volume of 759,820. The firm's 50 day moving average price is $13.24 and its 200 day moving average price is $13.70. Stoke Therapeutics has a 12 month low of $3.77 and a 12 month high of $17.58.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.52) by $0.05. The company had revenue of $4.89 million for the quarter, compared to the consensus estimate of $3.46 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%.

Insiders Place Their Bets

In related news, major shareholder Skorpios Trust sold 1,937,500 shares of Stoke Therapeutics stock in a transaction dated Thursday, September 19th. The shares were sold at an average price of $14.05, for a total transaction of $27,221,875.00. Following the completion of the transaction, the insider now directly owns 8,906,181 shares of the company's stock, valued at approximately $125,131,843.05. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 11.30% of the company's stock.

Hedge Funds Weigh In On Stoke Therapeutics

A number of large investors have recently made changes to their positions in the company. Lynx1 Capital Management LP boosted its stake in shares of Stoke Therapeutics by 40.3% during the 2nd quarter. Lynx1 Capital Management LP now owns 5,185,191 shares of the company's stock worth $70,052,000 after purchasing an additional 1,488,371 shares during the period. Redmile Group LLC boosted its position in Stoke Therapeutics by 93.2% in the 1st quarter. Redmile Group LLC now owns 5,073,049 shares of the company's stock valued at $68,486,000 after buying an additional 2,447,543 shares during the period. Baker BROS. Advisors LP boosted its position in Stoke Therapeutics by 65.9% in the 1st quarter. Baker BROS. Advisors LP now owns 3,368,443 shares of the company's stock valued at $45,474,000 after buying an additional 1,338,309 shares during the period. Vanguard Group Inc. boosted its position in Stoke Therapeutics by 4.1% in the 1st quarter. Vanguard Group Inc. now owns 1,715,554 shares of the company's stock valued at $23,160,000 after buying an additional 67,052 shares during the period. Finally, Assenagon Asset Management S.A. purchased a new stake in Stoke Therapeutics in the 2nd quarter valued at about $19,835,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.